(Q39791600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Angela Nebbioso

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Antonello Mai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Lucia Altucci

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

E Borbone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M T Berlingieri

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F De Bellis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

G Chiappetta

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

5 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

105-116

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19802013%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2009.306

9 February 2020

exact match

0 references

cites work

Acute myeloid leukemia: therapeutic impact of epigenetic drugs

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Specific activity of class II histone deacetylases in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Vorinostat in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

HDAC inhibitors: clinical update and mechanism-based potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Clearing the TRAIL for Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

The TRAIL apoptotic pathway in cancer onset, progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Discovery and development of SAHA as an anticancer agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Novel histone deacetylase inhibitors in the treatment of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

HDAC-class II specific inhibition involves HDAC proteasome-dependent degradation mediated by RANBP2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Histone deacetylase inhibitors: molecular mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Feijoa sellowiana derived natural Flavone exerts anti-cancer action displaying HDAC inhibitory activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306

Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.306